14:30 – 15:30 • Friday, 3rd October 2014

From Humans to Humans:
building a foundation for the future
of haemophilia A management

Sponsored Satellite Symposium

14:30	Welcome & Introduction Giancarlo Castaman Hemophilia Center, Careggi Hospital and University of Florence, Italy
14:35	The role of posttranslational modification on the quality of FVIII: insights and opportunities Christoph Kannicht Head of Molecular Biochemistry Berlin Octapharma
14:50	Nuwiq: clinical trial experience in children and adults with haemophilia A Sigurd Knaub Vice President Clinical R&D Haematology Octapharma AG
15:05	On the Way to Personalized Prophylaxis John Pasi Professor of Haemostasis and Thrombosis Barts and The London School of Medicine and Dentistry Haemophilia Centre Offices
15:20	Discussion and Conclusive Remarks Giancarlo Castaman Hemophilia Center, Careggi Hospital and University of Florence, Italy

Download the invitation here

 

 

 

Main topics emerging from this Symposium:

• How can rFVIII be improved?
• What happens to a protein after its translation?
• Role of posttranslational modifications (sulfation, glycosylation) on the quality of a recombinant FVIII
• Nuwiq: Functional insights gleaned from structure
• Overview of the clinical development plan for Nuwiq
• Efficacy and safety of Nuwiq in adult patients: on demand vs prophylaxis
• Nuwiq in children: Results from the phase III Study
• Current experience with personalised prophylaxis
• Future perspectives of personalized prophylaxis:
– Prophylaxis for adults with haemophilia
– Monitoring prophylaxis using global haemostasis assays
– PK and prophylaxis with novel FVIII concentrates
– The NuPreviq study: a multicentre clinical study for personalised prophylaxis